LA SUITE APRÈS LA PUBLICITÉ

The National Biosafety Management Agency – NBMA has ordered an immediate suspension of four newly registered genetically modified – GM cotton varieties following the discovery of significant compliance abnormalities.

The varieties in question—MIC 561 BGII, MIC 563 BGII, BIOSEED-FIYAH CH1001, and BIOSEED-FIYAH CH1002—were reportedly registered by the National Committee on naming, registration and release of crop varieties on March 26, 2026. However, the NBMA asserts that this registration occurred without the mandatory biosafety approvals, bypassing the legal oversight required for transgenic crops in Nigeria.

The suspension stems from findings that confined field trials and multi-locational testing for these hybrids were conducted without prior authorization, inspection, or regulatory monitoring. Under the NBMA Act, no institution is permitted to engage in the commercial release or field testing of genetically modified organisms – GMOs without explicit agency consent.

The regulator emphasized that these unauthorized actions constitute a direct violation of national laws, prompting a directive to halt all further actions on these varieties while formal investigations and potential legal sanctions are pursued.

This regulatory clash highlights the ongoing friction surrounding biotechnology in Nigeria, which is currently among the six African nations leading in biotech adoption. While proponents argue that GM crops like cotton, maize, and cowpea are essential for food security and pest resistance, critics remain wary of environmental risks and the transparency of the approval process.

The recent controversy is further complicated by past reports of international influence on Nigeria’s GMO advocacy, raising public concerns regarding the independence and rigor of the country’s biosafety framework.

Despite the suspension, the NBMA has assured the public that there is no immediate evidence of risk to human health or the environment. The agency maintains that the current intervention is a proactive measure to ensure that all biotechnology activities align with international best practices and national safety standards.

As the investigation continues, the move serves as a stern reminder to developers and sister agencies that compliance with the established biosafety roadmap is non-negotiable for the commercialization of transgenic seeds in the Nigerian market.